GelteqGELS -13.03%8 FCF Yield % is -60.67 as of Jun. 26, 2026. GuruFocus rates GELS with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Gelteq ranks worse than 95.62% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Gelteq's Trailing 12-Month Free Cash Flow is $-3.94 Mil, and Market Cap is $6.50 Mil. Therefore, Gelteq's FCF Yield % for today is -60.67%.
The historical rank and industry rank for Gelteq's FCF Yield % or its related term are showing as below:
GELS'
s FCF Yield % Range Over the Past 10 Years
Min: -102.56 Med: -30.91 Max: -4.66
Current: -60.67
During the past 6 years, the highest FCF Yield % of Gelteq was -4.66%. The lowest was -102.56%. And the median was -30.91%.
GELS's FCF Yield % is ranked worse than 95.62% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs GELS: -60.67
Gelteq's FCF Margin % for the quarter that ended in Jun. 2025 was -1,350.93%.
Gelteq FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Gelteq FCF Yield % Related Terms
Gelteq FCF Yield % Historical Data
* Premium members only.
The historical data trend for Gelteq's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gelteq's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelteq FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gelteq's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Gelteq's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gelteq (GELS) has a FCF Yield % of -60.67 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gelteq and its competitors. According to the industry distribution chart, Gelteq ranks #961 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is Gelteq's FCF Yield % too high?
Gelteq's current FCF Yield % is -60.67. Based on the distribution chart, Gelteq ranks #961 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gelteq has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's FCF Yield % compare to INM and LVRLF?
According to the Drug Manufacturers industry distribution chart, Gelteq ranks #961 out of 1005 companies for FCF Yield %. This places Gelteq in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gelteq and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelteq's current FCF Yield % is -60.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current FCF Yield % of -60.67. The current FCF Yield % is -60.67. Gelteq's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Gelteq (GELS), the current FCF Yield % is -60.67 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
8GF Score
Get the complete analysis for GELS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GELS has been successfully added to your 